Blog


Clickbank Ads
Sunday, October 20, 2019, 14:09

The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. 

In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the sleepiness of narcolepsy patients as compared to a placebo.

To continue reading this article click here


No comments yet.
(*) Required fields
Copyright ©2019 Narcolepsy, No One Gets It ! , All Rights Reserved. 
Website hosted by www.hostmate.biz
Hit counter: 4183
This website may use Cookies
This website may use Cookies in order to work better. At anytime you can disable or manage it in your browser's settings. Using our website, means you agree with Cookies usage.

OK, I understand or More Info
Cookies Information
This website may use Cookies in order to work better. At anytime you can disable or manage it in your browser's settings. Using our website, means you agree with Cookies usage.
OK, I understand